Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Guardant Health, Inc.

< Previous 1 2 3 4 5 6 Next >
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Proposed Public Offering of Common Stock
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Releases Inaugural ESG Report
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reports First Quarter 2023 Financial Results
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Additions to Leadership Team
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Musa Tariq Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in Upcoming March Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy
From Guardant Health, Inc.
Via Business Wire
Tickers GH
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.